National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 16 of 1994)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to provide a framework for the administration of national health services, including the Pharmaceutical Benefits Scheme (PBS). This legislative instrument, F2007B01112, represents a declaration under subsection 85(2AA) of the Act and addresses the need to periodically review and update the list of medications covered under the PBS. By removing Phenindione from the list of subsidised medications, the Act aims to ensure the PBS remains efficient and effective in providing necessary pharmaceuticals to the public. The policy objective, as stated in the declaration, is to align the PBS with current medical practices and evidence-based medicine, ensuring that taxpayer funds are used to subsidise medications that offer the best health outcomes for Australians. This legislative instrument demonstrates the ongoing commitment to refining the PBS to meet contemporary healthcare needs.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the cessation of Phenindione as a drug or medicinal preparation covered under Part VII of the Act. This legislative instrument impacts all entities and individuals involved in the provision, prescription, and supply of pharmaceutical benefits in Australia, including healthcare professionals, pharmacies, and patients who have been prescribed Phenindione. The Declaration effectively removes Phenindione from the list of drugs eligible for subsidies under the Pharmaceutical Benefits Scheme (PBS), which is a cornerstone of Australia's national health policy aimed at making prescription medicines affordable and accessible to the public. The jurisdictional reach of this Act is national, as it is a Commonwealth Act and applies across the entire country. There are no stated exclusions, exemptions, or thresholds in this particular Declaration. The scope and application of the Act may be further extended or restricted through subordinate instruments or subsequent amendments, which are subject to the provisions and authority granted under the National Health Act 1953.

Key Provisions

The main operative sections of this legislative instrument, specifically the declaration under subsection 85(2AA) of the National Health Act 1953, outline the cessation of the application of Part VII of the Act to Phenindione. Effective from 12 October 1994, this declaration mandates that Phenindione is no longer considered a drug or medicinal preparation subject to the provisions of Part VII (section 2). This part of the Act typically pertains to the regulation of pharmaceuticals, including those listed on the Pharmaceutical Benefits Scheme (PBS). By removing Phenindione from this list, the declaration effectively de-lists the drug, meaning it will no longer be eligible for subsidies under the PBS. The obligations and requirements imposed by this Act on the parties it governs include the necessity for the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health, acting as the Delegate of the Minister for Human Services and Health, to consult with the Pharmaceutical Benefits Advisory Committee before making such a declaration (subsection 85(2AB)). This ensures that the decision to de-list Phenindione is based on thorough and expert advice, maintaining the integrity and efficacy of the PBS. Furthermore, the Act necessitates that the declaration be formally documented and dated, as evidenced by the signature of David Trevor Graham on 6 October 1994. In terms of consequences for breach, the Act does not explicitly state offences, penalties, or civil/criminal consequences for non-compliance with this declaration. However, any failure to adhere to the Act's provisions, such as de-listing a drug without proper consultation or advisory input, could potentially lead to legal repercussions. These might include judicial review or other administrative actions to ensure compliance with the legislative intent. The penalties for such actions would depend on the specific breach and the resultant legal proceedings, but they could range from corrective actions to more severe penalties as deemed appropriate by the courts.